Journal of Pathology and Translational Medicine

Original Articles

Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01): Bo Mi Ku, Mi Hwa Heo, Joo-Hang Kim, Byoung Chul Cho, Eun Kyung Cho, Young Joo Min, Ki Hyeong Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Tae Jung Kim, Ho Yun Lee, Hojoong Kim, Kyung-Jong Lee, Myung-Ju Ahn; J Pathol Transl Med. 2018;52(3):148-156. Published online March 26, 2018; DOI: https://doi.org/10.4132/jptm.2018.03.12

7,809 View
301 Download
16 Web of Science
13 Crossref

Background
Non-small cell lung cancer (NSCLC) is a common type of cancer with poor prognosis. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in NSCLC might help predict patient outcomes and guide treatment. The aim of this study was to evaluate the clinical adequacy of molecular testing using next-generation sequencing (NGS) for small biopsy samples and characterize the mutational landscape of Korean patients with advanced NSCLC.
Methods
DNA was extracted from small biopsy samples of 162 patients with advanced NSCLC. Targeted NGS of genomic alterations was conducted using Ion AmpliSeq Cancer Hotspot Panel v2.
Results
The median age of patients was 64 years (range, 32 to 83 years) and the majority had stage IV NSCLC at the time of cancer diagnosis (90%). Among the 162 patients, 161 patients (99.4%) had novel or hotspot mutations (range, 1 to 21 mutated genes). Mutations were found in 41 genes. Three of the most frequently mutated genes were TP53 (151, 93.2%), KDR (104, 64.2%), and epidermal growth factor receptor (EGFR; 69, 42.6%). We also observed coexistence of EGFR and other oncogene (such as KRAS, PIC3CA, PTEN, and STK11) mutations. Given that 69.6% (48/69) of EGFR mutant patients were treated with EGFR tyrosine kinase inhibitors, EGFR mutant status had higher prognostic ability in this study.
Conclusions
These results suggest that targeted NGS using small biopsy samples is feasible and allows for the detection of both common and rare mutations in NSCLC.

Citations

Citations to this article as recorded by

PTEN, PTENP1, microRNAs, and ceRNA Networks: Precision Targeting in Cancer Therapeutics
Glena Travis, Eileen M. McGowan, Ann M. Simpson, Deborah J. Marsh, Najah T. Nassif
Cancers.2023; 15(20): 4954. CrossRef
Worldwide Prevalence of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis
Barbara Melosky, Kato Kambartel, Maik Häntschel, Margherita Bennetts, Dana J. Nickens, Julia Brinkmann, Antonin Kayser, Michael Moran, Federico Cappuzzo
Molecular Diagnosis & Therapy.2022; 26(1): 7. CrossRef
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef
Suitability of transbronchial brushing cytology specimens for next‐generation sequencing in peripheral lung cancer
Naoki Furuya, Shingo Matsumoto, Kazutaka Kakinuma, Kei Morikawa, Takeo Inoue, Hisashi Saji, Koichi Goto, Masamichi Mineshita
Cancer Science.2021; 112(1): 380. CrossRef
KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway
Yitong Xu, Chenglong Wang, Xizi Jiang, Yao Zhang, Hongbo Su, Jun Jiang, Hongjiu Ren, Xueshan Qiu
Cell Death & Disease.2021;[Epub] CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion
Quincy S. Chu
Therapeutic Advances in Medical Oncology.2020; 12: 175883591989575. CrossRef
Concomitant Mutations in EGFR 19Del/L858R Mutation and Their Association with Response to EGFR-TKIs in NSCLC Patients

Hengrui Liang, Caichen Li, Yi Zhao, Shen Zhao, Jun Huang, Xiuyu Cai, Bo Cheng, Shan Xiong, Jianfu Li, Wei Wang, Changbin Zhu, Weiwei Li, Jianxing He, Wenhua Liang
Cancer Management and Research.2020; Volume 12: 8653. CrossRef
Prognostic role of Rab27A and Rab27B expression in patients with non‐small cell lung carcinoma
Hyun Min Koh, Dae Hyun Song
Thoracic Cancer.2019; 10(2): 143. CrossRef
PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1
Jongmin Lee, Chan Kwon Park, Hyoung‐Kyu Yoon, Young Jo Sa, In Sook Woo, Hyo Rim Kim, Sue Youn Kim, Tae‐Jung Kim
Thoracic Cancer.2019; 10(1): 103. CrossRef
Targeted Next-Generation Sequencing Validates the Use of Diagnostic Biopsies as a Suitable Alternative to Resection Material for Mutation Screening in Colorectal Cancer
Hersh A. Ham-Karim, Henry Okuchukwu Ebili, Kirsty Manger, Wakkas Fadhil, Narmeen S. Ahmad, Susan D. Richman, Mohammad Ilyas
Molecular Diagnosis & Therapy.2019; 23(3): 383. CrossRef
Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing
Hidenori Kage, Shinji Kohsaka, Aya Shinozaki‐Ushiku, Yoshihisa Hiraishi, Jiro Sato, Kazuhiro Nagayama, Tetsuo Ushiku, Daiya Takai, Jun Nakajima, Kiyoshi Miyagawa, Hiroyuki Aburatani, Hiroyuki Mano, Takahide Nagase
Cancer Science.2019; 110(8): 2652. CrossRef
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
Anastasios Gkountakos, Giulia Sartori, Italia Falcone, Geny Piro, Ludovica Ciuffreda, Carmine Carbone, Giampaolo Tortora, Aldo Scarpa, Emilio Bria, Michele Milella, Rafael Rosell, Vincenzo Corbo, Sara Pilotto
Cancers.2019; 11(8): 1141. CrossRef

Transformation to Small Cell Lung Cancer of Pulmonary Adenocarcinoma: Clinicopathologic Analysis of Six Cases: Soomin Ahn, Soo Hyun Hwang, Joungho Han, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Woong-Yang Park; J Pathol Transl Med. 2016;50(4):258-263. Published online May 10, 2016; DOI: https://doi.org/10.4132/jptm.2016.04.19

11,172 View
242 Download
47 Web of Science
41 Crossref

Abstract PDF

Background
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are considered the first line treatment for a subset of EGFR-mutated non-small cell lung cancer (NSCLC) patients. Although transformation to small cell lung cancer (SCLC) is one of the known mechanisms of resistance to EGFR TKIs, it is not certain whether transformation to SCLC is exclusively found as a mechanism of TKI resistance in EGFR-mutant tumors.
Methods
We identified six patients with primary lung adenocarcinoma that showed transformation to SCLC on second biopsy (n = 401) during a 6-year period. Clinicopathologic information was analyzed and EGFR mutation results were compared between initial and second biopsy samples.
Results
Six patients showed transformation from adenocarcinoma to SCLC, of which four were pure SCLCs and two were combined adenocarcinoma and SCLCs. Clinically, four cases were EGFR-mutant tumors from non-smoking females who underwent TKI treatment, and the EGFR mutation was retained in the transformed SCLC tumors. The remaining two adenocarcinomas were EGFR wild-type, and one of these patients received EGFR TKI treatment.
Conclusions
NSCLC can acquire a neuroendocrine phenotype with or without EGFR TKI treatment.

Citations

Citations to this article as recorded by

Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer
Xi Ding, Min-xing Shi, Di Liu, Jing-xue Cao, Kai-xuan Zhang, Run-dong Zhang, Li-ping Zhang, Kai-xing Ai, Bo Su, Jie Zhang
Cell Communication and Signaling.2024;[Epub] CrossRef
The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
Alessandra Ferro, Gian Marco Marinato, Cristiana Mulargiu, Monica Marino, Giulia Pasello, Valentina Guarneri, Laura Bonanno
Critical Reviews in Oncology/Hematology.2024; 196: 104295. CrossRef
Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
Kresimir Tomic, Kristina Krpina, Lara Baticic, Miroslav Samarzija, Semir Vranic
Journal of Drug Targeting.2024; 32(5): 499. CrossRef
Transcriptomic Heterogeneity of EGFR-Mutant Non–Small Cell Lung Cancer Evolution Toward Small-Cell Lung Cancer
Songji Oh, Jaemoon Koh, Tae Min Kim, Soyeon Kim, Jeonghwan Youk, Miso Kim, Bhumsuk Keam, Yoon Kyung Jeon, Ja-Lok Ku, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
Clinical Cancer Research.2024; 30(20): 4729. CrossRef
Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
Nunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, Paola Bossi, Erika Stucchi, Fabio Conforti, Emilia Cocorocchio, Daniele Laszlo, Laura Pala, Emma Zattarin, Chiara Catania
Current Oncology.2023; 30(3): 3494. CrossRef
Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
Giuseppe Giaccone, Yongfeng He
Seminars in Cancer Biology.2023; 94: 1. CrossRef
Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
Sushanta Halder, Soumi Basu, Shobhit P. Lall, Apar K. Ganti, Surinder K. Batra, Parthasarathy Seshacharyulu
Expert Opinion on Therapeutic Targets.2023; 27(4-5): 305. CrossRef
Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis
Jinhe Xu, Lihuan Xu, Baoshan Wang, Wencui Kong, Ying Chen, Zongyang Yu
Frontiers in Oncology.2022;[Epub] CrossRef
Small cell lung cancer transformation: From pathogenesis to treatment
Xiaomeng Yin, Yueyi Li, Hang Wang, Tingting Jia, Enli Wang, Yuling Luo, Yuhao Wei, Zeyi Qin, Xuelei Ma
Seminars in Cancer Biology.2022; 86: 595. CrossRef
Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Journal of Clinical Medicine.2022; 11(5): 1429. CrossRef
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman
International Journal of Molecular Sciences.2022; 23(8): 4164. CrossRef
Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets
Ugo Testa, Elvira Pelosi, Germana Castelli
Onco.2022; 2(3): 186. CrossRef
Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon
Xiao Chu, Yuyin Xu, Ye Li, Yue Zhou, Li Chu, Xi Yang, Jianjiao Ni, Yida Li, Tiantian Guo, Zhiqin Zheng, Qiang Zheng, Qianlan Yao, Yuan Li, Xiaoyan Zhou, Zhengfei Zhu
Lung Cancer.2022; 169: 22. CrossRef
Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
Ling Chen, Yangqingqing Zhou, Chaosheng Gan, XiaoLi Wang, Yihui Liu, Chunhui Dong, Ruiyuan He, Jin Yang
Cancer Investigation.2022; 40(7): 590. CrossRef
Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
Hao Liu, Li-Hong Chen, Zhi-Hui Zhang, Ning Wang, Si-Hui Zhuang, Hao Chen, Jin Du, Li-Juan Pang, Yan Qi
Frontiers in Oncology.2022;[Epub] CrossRef
Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, João Victor Machado Alessi, Andrea Kazumi Shimada, José Flávio Gomes Marin, Anamaria Aranha Ca
npj Precision Oncology.2021;[Epub] CrossRef
Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases
Cai-Bao Jin, Ling Yang
World Journal of Clinical Cases.2021; 9(18): 4617. CrossRef
Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
Naoyuki Nishiya, Yusuke Oku, Chie Ishikawa, Tsutomu Fukuda, Shingo Dan, Tetsuo Mashima, Masaru Ushijima, Yoko Furukawa, Yuka Sasaki, Keishi Otsu, Tomoko Sakyo, Masanori Abe, Honami Yonezawa, Fumito Ishibashi, Masaaki Matsuura, Akihiro Tomida, Hiroyuki Sei
Cancer Science.2021; 112(5): 1963. CrossRef
Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases
Qian Shen, Jingjing Qu, Lingyan Sheng, Qiqi Gao, Jianying Zhou
Frontiers in Oncology.2021;[Epub] CrossRef
Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
Kyoungmin Lee, Deokhoon Kim, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim
European Journal of Cancer.2021; 148: 202. CrossRef
Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Junling Li, Puyuan Xing
Thoracic Cancer.2021; 12(19): 2585. CrossRef
EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs
Chih-An Lin, Sung-Liang Yu, Hsuan-Yu Chen, Huei-Wen Chen, Shr-Uen Lin, Chia-Ching Chang, Chong-Jen Yu, Pan-Chyr Yang, Chao-Chi Ho
Journal of Thoracic Oncology.2019; 14(3): 513. CrossRef
The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer
Haiyan Yang, Li Liu, Chunhua Zhou, Yi Xiong, Yijuan Hu, Nong Yang, Jingjing Qu
Medicine.2019; 98(12): e14893. CrossRef
Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents
Olayinka O. Ajani, Martins T. Nlebemuo, Joseph A. Adekoya, Kehinde O. Ogunniran, Tolutope O. Siyanbola, Christiana O. Ajanaku
Acta Pharmaceutica.2019; 69(2): 177. CrossRef
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu
Critical Reviews in Oncology/Hematology.2018; 123: 149. CrossRef
Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review
Yangyang Liu
Cancer Biology & Therapy.2018; 19(6): 445. CrossRef
Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
Jongmin Sim, Hyunjin Kim, Jiyeon Hyeon, Yoon-La Choi, Joungho Han
Journal of Korean Medical Science.2018;[Epub] CrossRef
Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, Hatim Husain, Daniel B. Costa, Philip Tracy, Nora Feeney, Lynette M. Sholl, Suzanne E. Dahlberg, Amanda J. Redig, David J. Kwiatkowski, Michael S. Rabin, Cloud P. Paweletz, Kenneth S. Thress, Pasi A. Jänne
JAMA Oncology.2018; 4(11): 1527. CrossRef
Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer
Mong-Wei Lin, Kang-Yi Su, Te-Jen Su, Chia-Ching Chang, Jing-Wei Lin, Yi-Hsuan Lee, Sung-Liang Yu, Jin-Shing Chen, Min-Shu Hsieh
Lung Cancer.2018; 125: 282. CrossRef
Transformation to small‑cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma
Hongyang Lu, Bo Chen, Jing Qin, Fajun Xie, Na Han, Zhiyu Huang
Oncology Letters.2018;[Epub] CrossRef
Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature
Monalisa Hui, ShantveerG Uppin, BalaJoseph Stalin, G Sadashivudu
Lung India.2018; 35(2): 160. CrossRef
A rare case of squamous cell carcinoma lung with multiple locoregional recurrences and histological transformation
Ram Niwas, Shibdas Chakrabarti, Viswesvaran Balasubramanian, ManasKamal Sen, JagdishChander Suri
Lung India.2018; 35(6): 511. CrossRef
Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
Takuma Imakita, Kohei Fujita, Osamu Kanai, Tsuyoshi Terashima, Tadashi Mio
Respiratory Medicine Case Reports.2017; 21: 52. CrossRef
Pulmonary neuroendocrine tumor in a female wolf (Canis lupus lupus)
Ayako SHIRAKI, Toshinori YOSHIDA, Masahi KAWASHIMA, Hirotada MURAYAMA, Rei NAGAHARA, Nanao ITO, Makoto SHIBUTANI
Journal of Veterinary Medical Science.2017; 79(3): 588. CrossRef
Secondary biopsy of non‐oncogenic‐driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases
Maria C. Mengoli, Giulia Orsi, Filippo Lococo, Giulia Grizzi, Fausto Barbieri, Federica Bertolini, Giulio Rossi, Silvia Novello
Thoracic Cancer.2017; 8(4): 359. CrossRef
Small-cell lung cancer in never smokers: The clinicopathological features including the prognosis
Masahiro Yamasaki, Naomi Saito, Wakako Daido, Sayaka Ishiyama, Naoko Deguchi, Masaya Taniwaki, Akio Sakatani, Megumu Fujihara, Nobuyuki Ohashi, Ken-ichi Arita
Cancer Treatment and Research Communications.2017; 12: 1. CrossRef
Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong-Wan Kim, Dae Seog Heo, Young Tae Kim, Jin-Soo Kim, Se Hyun Kim, Jong Seok Lee, Se-Hoon Lee, Keunchil Park, Ja-Lok Ku, Yoon Kyung Jeon, Doo Hyun
Journal of Clinical Oncology.2017; 35(26): 3065. CrossRef
Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
Thomas John, Jeffrey J Bowden, Stephen Clarke, Stephen B Fox, Kerryn Garrett, Keith Horwood, Christos S Karapetis
Asia-Pacific Journal of Clinical Oncology.2017; 13(4): 296. CrossRef
Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Hyung Kyu Park, Youjeong Seo, Yoon-La Choi, Myung-Ju Ahn, Joungho Han
Journal of Pathology and Translational Medicine.2017; 51(4): 441. CrossRef
Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
Ahsan Wahab, Kavitha Kesari, Siddique Chaudhary, Mahin Khan, Hafiz Khan, Susan Smith, Yanis Boumber
Cancer Biology & Therapy.2017; 18(12): 940. CrossRef
The expression of S100B protein in serum of patients with brain metastases from small-cell lung cancer and its clinical significance
Shanling Mu, Hong Ma, Jun Shi, Dezhi Zhen
Oncology Letters.2017;[Epub] CrossRef

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases: Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um; J Pathol Transl Med. 2016;50(3):197-203. Published online April 18, 2016; DOI: https://doi.org/10.4132/jptm.2016.03.09

18,047 View
305 Download
69 Web of Science
62 Crossref

Abstract PDF

Background
Although epidermal growth factor receptor (EGFR), v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) were thought to be mutually exclusive, some tumors harbor concomitant mutations. Discovering a driver mutation on the basis of morphologic features and therapeutic responses with mutation analysis can be used to understand pathogenesis and predict resistance in targeted therapy.
Methods
In 6,637 patients with NSCLC, 12 patients who had concomitant mutations were selected and clinicopathologic features were reviewed. Clinical characteristics included sex, age, smoking history, previous treatment, and targeted therapy with response and disease-free survival. Histologic features included dominant patterns, nuclear and cytoplasmic features.
Results
All patients were diagnosed with adenocarcinoma and had an EGFR mutation. Six patients had concomitant KRAS mutations and the other six had ALK mutations. Five of six EGFR-KRAS mutation patients showed papillary and acinar histologic patterns with hobnail cells. Three of six received EGFR tyrosine kinase inhibitor (TKI) and showed partial response for 7–29 months. All six EGFR-ALK mutation patients showed solid or cribriform patterns and three had signet ring cells. Five of six EGFR-ALK mutation patients received EGFR TKI and/or ALK inhibitor and four showed partial response or stable disease, except for one patient who had acquired an EGFR mutation.
Conclusions
EGFR and ALK mutations play an important role as driver mutations in double mutated NSCLC, and morphologic analysis can be used to predict treatment response.

Citations

Citations to this article as recorded by

Artificial Intelligence in Lung Cancer Imaging: From Data to Therapy
Michaela Cellina, Giuseppe De Padova, Nazarena Caldarelli, Dario Libri, Maurizio Cè, Carlo Martinenghi, Marco AlÃ¬, Sergio Papa, Gianpaolo Carrafiello
Critical Reviews™ in Oncogenesis.2024; 29(2): 1. CrossRef
Artificial Intelligence for Cardiothoracic Imaging: Overview of Current and Emerging Applications
Bruno Hochhegger, Romulo Pasini, Alysson Roncally Carvalho, Rosana Rodrigues, Stephan Altmayer, Leonardo Kayat Bittencourt, Edson Marchiori, Reza Forghani
Seminars in Roentgenology.2023; 58(2): 184. CrossRef
Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study
Diego F. Chamorro, Andrés F. Cardona, July Rodríguez, Alejandro Ruiz-Patiño, Oscar Arrieta, Darwin A. Moreno-Pérez, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Dora V. Ardila, Lucia Viola, Gonzalo Recondo, Juan B. Blaquier, Claudio Martín, Luis Raez, Su
Targeted Oncology.2023; 18(3): 425. CrossRef
Histone deacetylase inhibitor belinostat regulates metabolic reprogramming in killing KRAS‐mutant human lung cancer cells
Rebecca M. Peter, Md. Shahid Sarwar, Sarah Z. Mostafa, Yujue Wang, Xiaoyang Su, Ah‐Ng Kong
Molecular Carcinogenesis.2023; 62(8): 1136. CrossRef
Differential Distribution of Brain Metastases from Non-Small Cell Lung Cancer Based on Mutation Status
Bihong T. Chen, Taihao Jin, Ningrong Ye, Sean W. Chen, Russell C. Rockne, Stephanie Yoon, Isa Mambetsariev, Ebenezer Daniel, Ravi Salgia
Brain Sciences.2023; 13(7): 1057. CrossRef
Clinicopathological features and prognostic significance of pulmonary adenocarcinoma with signet ring cell components: meta-analysis and SEER analysis
Yang Tan, Ying-he Huang, Jia-wen Xue, Rui Zhang, Run Liu, Yan Wang, Zhen-Bo Feng
Clinical and Experimental Medicine.2023; 23(8): 4341. CrossRef
Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer cells
Wei-Jyun Hua, Hsin Yeh, Zhi-Hu Lin, Ai-Jung Tseng, Li-Chen Huang, Wei-Lun Qiu, Tsung-Hsi Tu, Ding-Han Wang, Wei-Hung Hsu, Wei-Lun Hwang, Tung-Yi Lin
Cancer Letters.2023; 578: 216458. CrossRef
Next generation sequencing for detection ofEGFRalterations in NSCLC: is more better?
Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Parveen Jain, Anurag Mehta
Journal of Clinical Pathology.2022; 75(3): 164. CrossRef
Enkurin domain containing 1 (ENKD1) regulates the proliferation, migration and invasion of non‐small cell lung cancer cells
Ting Song, Peng Zhou, Chunjiao Sun, Na He, Haixia Li, Jie Ran, Jun Zhou, Yue Wu, Min Liu
Asia-Pacific Journal of Clinical Oncology.2022;[Epub] CrossRef
Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
Jia-Xin Li, Run-Ze Li, Lin-Rui Ma, Peng Wang, Dong-Han Xu, Jie Huang, Li-Qi Li, Ling Tang, Ying Xie, Elaine Lai-Han Leung, Pei-Yu Yan
Frontiers in Pharmacology.2022;[Epub] CrossRef
Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis
Shuhei Ueshima, Jia Fang
Oncogene.2022; 41(24): 3370. CrossRef
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
A. Passaro, N. Leighl, F. Blackhall, S. Popat, K. Kerr, M.J. Ahn, M.E. Arcila, O. Arrieta, D. Planchard, F. de Marinis, A.M. Dingemans, R. Dziadziuszko, C. Faivre-Finn, J. Feldman, E. Felip, G. Curigliano, R. Herbst, P.A. Jänne, T. John, T. Mitsudomi, T.
Annals of Oncology.2022; 33(5): 466. CrossRef
Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
Begoña O. Alen, Lara S. Estévez-Pérez, María Teresa Hermida-Romero, Ana Reguera-Arias, Rosario García-Campelo, Mercedes de la Torre-Bravos, Ángel Concha
Cancers.2022; 14(14): 3323. CrossRef
Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer
Yock Ping Chow, Norziha Zainul Abidin, Ken Siong Kow, Lye Mun Tho, Chieh Lee Wong, Rama Krishna Kancha
PLOS ONE.2022; 17(10): e0276161. CrossRef
Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
Ming-Hung Huang, Jih-Hsiang Lee, Pei-Shan Hung, James Chih-Hsin Yang
JTO Clinical and Research Reports.2022; 3(11): 100405. CrossRef
Artificial Intelligence in Lung Cancer Imaging: Unfolding the Future
Michaela Cellina, Maurizio Cè, Giovanni Irmici, Velio Ascenti, Natallia Khenkina, Marco Toto-Brocchi, Carlo Martinenghi, Sergio Papa, Gianpaolo Carrafiello
Diagnostics.2022; 12(11): 2644. CrossRef
A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
Yanxia Liu, Yuan Gao, Ying Wang, Cong Zhao, Zhiyun Zhang, Baolan Li, Tongmei Zhang
BMC Cancer.2022;[Epub] CrossRef
High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
Didik Setyo Heriyanto, Vincent Laiman, Nikko Vanda Limantara, Widyan Putra Anantawikrama, Fara Silvia Yuliani, Rita Cempaka, Sumadi Lukman Anwar
BMC Research Notes.2022;[Epub] CrossRef
Kirsten Rat Sarcoma Mutation in South Indians with Non-Small Lung Cancer
Gautam Balaram, Renjan Thomas, Suhas N. Ghorpade, Prarthana V. Kowsik, Baby Dharman, Yogesh Shivakumar, Shekar Patil, Satheesh Chiradoni Thungappa, HP Shashidhara, Somorat Bhattacharjee, Sridhar Papaiah Susheela, Radheshyam Naik, Srinivas Belagutty Jayapp
Journal of Precision Oncology.2022; 2(1): 3. CrossRef
Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non–small-cell lung cancer
Songbai Zheng, Xiaodan Wang, Ying Fu, Beibei Li, Jianhua Xu, Haifang Wang, Zhen Huang, Hui Xu, Yurong Qiu, Yaozhou Shi, Kui Li
Bioengineered.2021; 12(1): 791. CrossRef
How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer
Pirmin Schlicke, Christina Kuttler, Christian Schumann
Theoretical Biology and Medical Modelling.2021;[Epub] CrossRef
A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
Ki-Chang Lee, Jiwon Koh, Doo Hyun Chung, Yoon Kyung Jeon
Journal of Pathology and Translational Medicine.2021; 55(2): 139. CrossRef
Malfeasance of KRAS mutations in carcinogenesis
Rupal Tripathi, Shrinidhi Nathany, Anurag Mehta, Ullas Batra, Sakshi Mattoo, Mansi Sharma
Clinical and Experimental Medicine.2021; 21(3): 439. CrossRef
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
Giorgia Nardo, Jessica Carlet, Ludovica Marra, Laura Bonanno, Alice Boscolo, Alessandro Dal Maso, Andrea Boscolo Bragadin, Stefano Indraccolo, Elisabetta Zulato
Frontiers in Oncology.2021;[Epub] CrossRef
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
Valerio Gristina, Maria La Mantia, Antonio Galvano, Sofia Cutaia, Nadia Barraco, Marta Castiglia, Alessandro Perez, Marco Bono, Federica Iacono, Martina Greco, Katia Calcara, Valentina Calò, Sergio Rizzo, Lorena Incorvaia, Maria Chiara Lisanti, Giulia San
Journal of Molecular Pathology.2021; 2(2): 173. CrossRef
Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
OncoTargets and Therapy.2021; Volume 14: 4671. CrossRef
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Kulshrestha Ritu, Pawan Kumar, Amit Singh, K. Nupur, Sonam Spalgias, Parul Mrigpuri, Rajkumar
Molecular Biomedicine.2021;[Epub] CrossRef
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report
Janna-Lisa Velthaus, Peter Iglauer, Ronald Simon, Carsten Bokemeyer, Peter Bannas, Niklas Beumer, Charles D. Imbusch, Eray Goekkurt, Sonja Loges
Oncology Research and Treatment.2021; 44(9): 495. CrossRef
Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis
Lu Tong, Shihui Shen, Quan Huang, Junjiang Fu, Tianzhen Wang, Linian Pan, Pei Zhang, Geng Chen, Tingmei Huang, Ke Li, Qingwu Liu, Shaofang Xie, Xiao Yang, Robb E. Moses, Xiaotao Li, Lei Li
Cell Death & Differentiation.2020; 27(6): 1795. CrossRef
Circulating Cell-Free Dna As A Diagnostic and Prognostic Biomarker for Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
Zhoumiao Chen, Huiwen Miao, Qingxin Zeng, Shaohua Xu, Zhao Chen, Kai Liu
Biomarkers in Medicine.2020; 14(7): 587. CrossRef
Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
Yoshinori Tsukumo, Mikihiko Naito, Takayoshi Suzuki, Srikumar Chellappan
PLOS ONE.2020; 15(3): e0229712. CrossRef
KRAS oncogene may be another target conquered in non‐small cell lung cancer (NSCLC)
Hanxiao Chen, Jun Zhao
Thoracic Cancer.2020; 11(12): 3425. CrossRef
Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico
Ruifang Zheng, Zhiwei Yin, Albert Alhatem, Derek Lyle, Bei You, Andrew S. Jiang, Dongfang Liu, Zsolt Jobbagy, Qing Wang, Seena Aisner, Jie-Gen Jiang
Cancers.2020; 12(12): 3492. CrossRef
Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications
Robin Imperial, Omer M Toor, Arif Hussain, Janakiraman Subramanian, Ashiq Masood
Seminars in Cancer Biology.2019; 54: 14. CrossRef
Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India
Varsha Singh, Prerna Guleria, Prabhat Singh Malik, Anant Mohan, Sanjay Thulkar, R M Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Deepali Jain
Current Problems in Cancer.2019; 43(5): 391. CrossRef
Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers
Federico De Marchi, Lisa Haley, Henderson Fryer, Junaid Ibrahim, Katie Beierl, Gang Zheng, Christopher D. Gocke, James R. Eshleman, Deborah Belchis, Peter Illei, Ming-Tseh Lin
Archives of Pathology & Laboratory Medicine.2019; 143(2): 174. CrossRef
A sequential Monte Carlo algorithm for inference of subclonal structure in cancer
Oyetunji E. Ogundijo, Kaiyi Zhu, Xiaodong Wang, Dimitris Anastassiou, Xiang Li
PLOS ONE.2019; 14(1): e0211213. CrossRef
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
Anna Rachiglio, Francesca Fenizia, Maria Piccirillo, Domenico Galetta, Lucio Crinò, Bruno Vincenzi, Emiddio Barletta, Carmine Pinto, Francesco Ferraù, Matilde Lambiase, Agnese Montanino, Cristin Roma, Vienna Ludovini, Elisabetta Montagna, Antonella De Luc
Cancers.2019; 11(3): 341. CrossRef
Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong, Li Zhang, Yalan Bi, Mengzhao Wang
EBioMedicine.2019; 42: 304. CrossRef
Anaplastic Lymphoma Kinase (ALK)-positive Tumors
Rohan Gupta, Idoroenyi Amanam, Syed Rahmanuddin, Isa Mambetsariev, Yingyu Wang, Charity Huang, Karen Reckamp, Lalit Vora, Ravi Salgia
American Journal of Clinical Oncology.2019; 42(4): 337. CrossRef
Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF
Xibin Zhuang, Chao Zhao, Jiayu Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou
Cancer Medicine.2019; 8(6): 2858. CrossRef
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu, Linea C. Melchior, Edyta M. Urbanska, Jan N. Jakobsen, Karin de Stricker, Morten Grauslund, Jens B. Sørensen
Cancers.2019; 11(7): 923. CrossRef
Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
BMC Cancer.2019;[Epub] CrossRef
Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS‐G12D mutation and P53 knockout
Meiqin Zhang, Nan Jiang, Renjie Cui, Sichen Du, Huayuan Ou, Tinglan Chen, Runsheng Ge, Duan Ma, Jin Zhang
Journal of Cellular and Molecular Medicine.2019; 23(10): 6978. CrossRef
Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes
Erica K. Barnell, Adam Waalkes, Matt C. Mosior, Kelsi Penewit, Kelsy C. Cotto, Arpad M. Danos, Lana M. Sheta, Katie M. Campbell, Kilannin Krysiak, Damian Rieke, Nicholas C. Spies, Zachary L. Skidmore, Colin C. Pritchard, Todd A. Fehniger, Ravindra Uppalur
JCO Clinical Cancer Informatics.2019; (3): 1. CrossRef
EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
Maria Colombino, Panagiotis Paliogiannis, Antonio Cossu, Davide Adriano Santeufemia, Maria Cristina Sini, Milena Casula, Grazia Palomba, Antonella Manca, Marina Pisano, Valentina Doneddu, Giuseppe Palmieri
BMC Pulmonary Medicine.2019;[Epub] CrossRef
Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature
Nishitha Thumallapally, Hana Yu, Mohammad Farhan, Uroosa Ibrahim, Maricel Odiami
Journal of Pharmacy Practice.2018; 31(2): 244. CrossRef
Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC
Nele Van Der Steen, Yves Mentens, Marc Ramael, Leticia G. Leon, Paul Germonpré, Jose Ferri, David R. Gandara, Elisa Giovannetti, Godefridus J. Peters, Patrick Pauwels, Christian Rolfo
Clinical Lung Cancer.2018; 19(1): 35. CrossRef
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent, Ignacio Gil-Bazo
Molecular Cancer.2018;[Epub] CrossRef
Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib
Akira Yokoyama, Atsuhisa Tamura, Kazuko Miyakawa, Kei Kusaka, Masahiro Shimada, Takashi Hirose, Hirotoshi Matsui, Masashi Kitani, Akira Hebisawa, Ken Ohta
Internal Medicine.2018; 57(16): 2377. CrossRef
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations
Biagio Ricciuti, Sara Baglivo, Vienna Ludovini, Angelo Sidoni, Giulio Metro, Marta Brambilla, Annamaria Siggillino, Maria Sole Reda, Alberto Rebonato, Daniele Maiettini, Rita Chiari
Lung Cancer.2018; 120: 70. CrossRef
Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
Jan Nyrop Jakobsen, Eric Santoni-Rugiu, Morten Grauslund, Linea Melchior, Jens Benn Sørensen
Oncotarget.2018; 9(40): 26195. CrossRef
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
Marzia Del Re, Eleonora Rofi, Giuliana Restante, Stefania Crucitta, Elena Arrigoni, Stefano Fogli, Massimo Di Maio, Iacopo Petrini, Romano Danesi
Oncotarget.2018; 9(5): 6630. CrossRef
Alk Immunohistochemistry is Highly Sensitive and Specific for the Detection of Alk Translocated Lung Adenocarcinomas: Lessons from An Audit of Lung Cancer Molecular Testing
YC Kheng, K Walsh, L Williams, WA Wallace, DJ Harrison, A Oniscu
Journal of the Royal College of Physicians of Edinburgh.2018; 48(1): 20. CrossRef
Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
Alexios Matikas, Dimitrios Mistriotis, Vasilios Georgoulias, Athanasios Kotsakis
Critical Reviews in Oncology/Hematology.2017; 110: 1. CrossRef
Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Früh
Journal of Thoracic Oncology.2017; 12(4): 681. CrossRef
EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology
Vincent Thomas De Montpréville, Maria-Rosa Ghigna, Ludovic Lacroix, Antoinette Lemoine, Benjamin Besse, Olaf Mercier, Élie Fadel, Peter Dorfmuller, Thierry Le Chevalier
Pathology - Research and Practice.2017; 213(7): 793. CrossRef
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
Journal of Thoracic Oncology.2017; 12(8): 1233. CrossRef
Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)
Jean-Bernard Auliac, Isabelle Monnet, Catherine Dubos-Arvis, Anne Marie Chiappa, Nathalie Baize, Suzana Bota, Alain Vergnenegre, Helene Doubre, Chrystele Locher, Acya Bizieux, Gilles Robinet, Christos Chouaid
Targeted Oncology.2017; 12(6): 833. CrossRef
Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
Giuseppe Lo Russo, Martina Imbimbo, Giulia Corrao, Claudia Proto, Diego Signorelli, Milena Vitali, Monica Ganzinelli, Laura Botta, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino
Oncotarget.2017; 8(35): 59889. CrossRef
Management of non-small cell lung cancer in the era of personalized medicine
Gaetano Rocco, Alessandro Morabito, Alessandra Leone, Paolo Muto, Francesco Fiore, Alfredo Budillon
The International Journal of Biochemistry & Cell Biology.2016; 78: 173. CrossRef
A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation
Fumio Imamura, Takako Inoue, Madoka Kimura, Kazumi Nishino, Toru Kumagai
Respiratory Medicine Case Reports.2016; 19: 137. CrossRef

Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey: Sang Hwa Lee, Wan Seop Kim, Yoo Duk Choi, Jeong Wook Seo, Joung Ho Han, Mi Jin Kim, Lucia Kim, Geon Kook Lee, Chang Hun Lee, Mee Hye Oh, Gou Young Kim, Sun Hee Sung, Kyo Young Lee, Sun Hee Chang, Mee Sook Rho, Han Kyeom Kim, Soon Hee Jung, Se Jin Jang, The Cardiopulmonary Pathology Study Group of Korean Society of Pathologists; J Pathol Transl Med. 2015;49(6):481-488. Published online October 13, 2015; DOI: https://doi.org/10.4132/jptm.2015.09.14

10,642 View
99 Download
19 Web of Science
21 Crossref

Abstract PDF

Background
Analysis of mutations in the epidermal growth factor receptor gene (EGFR) is important for predicting response to EGFR tyrosine kinase inhibitors. The overall rate of EGFR mutations in Korean patients is variable. To obtain comprehensive data on the status of EGFR mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey. Methods: We obtained 1,753 reports on EGFR mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared EGFR mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status. Results: The overall EGFR mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. EGFR mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. EGFR mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC. Conclusions: EGFR mutation rates and statuses were similar to those in published data from other East Asian countries.

Citations

Citations to this article as recorded by

The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia
Noni Novisari Soeroso, Fannie Rizki Ananda, Johan Samuel Sitanggang, Noverita Sprinse Vinolina
F1000Research.2023; 11: 853. CrossRef
Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients
Changlong He, Chengcheng Wei, Jun Wen, Shi Chen, Ling Chen, Yue Wu, Yifan Shen, Huili Bai, Yangli Zhang, Xueping Chen, Xiaosong Li
Journal of Cancer Research and Clinical Oncology.2022; 148(2): 321. CrossRef
Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China
Jun-Ling Wang, Yu-Dong Fu, Yan-Hong Gao, Xiu-Ping Li, Qian Xiong, Rui Li, Bo Hou, Ruo-Shan Huang, Jun-Feng Wang, Jian-Kun Zhang, Jia-Ling Lv, Chao Zhang, Hong-Wei Li
Genes and Environment.2022;[Epub] CrossRef
Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
Min Yu, Xiaoyu Li, Xueqian Wu, Weiya Wang, Yanying Li, Yan Zhang, Shuang Zhang, Yongsheng Wang
Frontiers in Oncology.2022;[Epub] CrossRef
The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia
Noni Novisari Soeroso, Fannie Rizki Ananda, Johan Samuel Sitanggang, Noverita Sprinse Vinolina
F1000Research.2022; 11: 853. CrossRef
Adverse Event Profiles of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Adenocarcinoma Lung Patients in North Sumatera Population
Moh. Ramadhani Soeroso, Noni Novisari Soeroso, Setia Putra Tarigan, Elisna Syahruddin
Open Access Macedonian Journal of Medical Sciences.2022; 10(T7): 134. CrossRef
Landscape of EGFR mutations in lung adenocarcinoma: a single institute experience with comparison of PANAMutyper testing and targeted next-generation sequencing
Jeonghyo Lee, Yeon Bi Han, Hyun Jung Kwon, Song Kook Lee, Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2022; 56(5): 249. CrossRef
Traditional Chinese Medicine Syndromes are Associated with Driver Gene Mutations and Clinical Characteristics in Patients with Lung Adenocarcinoma
Jili Yang, Haiyan Lu, Niancai Jing, Bo Wang, Huanyu Guo, Shoukun Sun, Yue Zhang, Chan-Yen Kuo
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy
Yoonjung Kim, Saeam Shin, Kyung-A Lee
Cancer Cell International.2021;[Epub] CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Myung-Ju Ahn, Ji-Youn Han, Dong-Wan Kim, Byoung Chul Cho, Jin-Hyoung Kang, Sang-We Kim, James Chih-Hsin Yang, Tetsuya Mitsudomi, Jong Seok Lee
Cancer Research and Treatment.2020; 52(1): 284. CrossRef
Long non-coding RNA ATB promotes human non-small cell lung cancer proliferation and metastasis by suppressing miR-141-3p
Guojie Lu, Yaosen Zhang, Klaus Roemer
PLOS ONE.2020; 15(2): e0229118. CrossRef
Prognostic Role of S100A8 and S100A9 Protein Expressions in Non-small Cell Carcinoma of the Lung
Hyun Min Koh, Hyo Jung An, Gyung Hyuck Ko, Jeong Hee Lee, Jong Sil Lee, Dong Chul Kim, Jung Wook Yang, Min Hye Kim, Sung Hwan Kim, Kyung Nyeo Jeon, Gyeong-Won Lee, Se Min Jang, Dae Hyun Song
Journal of Pathology and Translational Medicine.2019; 53(1): 13. CrossRef
Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
Yongchun Zhou, Yuhui Ma, Hutao Shi, Yaxi Du, Yunchao Huang
Scientific Reports.2018;[Epub] CrossRef
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
Yong Won Choi, Jin-Hyuk Choi
The Korean Journal of Internal Medicine.2017; 32(3): 422. CrossRef
Molecular Testing of Lung Cancers
Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
Journal of Pathology and Translational Medicine.2017; 51(3): 242. CrossRef
MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
Journal of Thoracic Oncology.2017; 12(8): 1233. CrossRef
Epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
Yongchun Zhou, Yanlong Yang, Chenggang Yang, Yunlan Chen, Changshao Yang, Yaxi Du, Guangqiang Zhao, Yinjin Guo, Lianhua Ye, Yunchao Huang
Oncotarget.2017; 8(9): 15023. CrossRef
Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
Seung Eun Lee, So-Young Lee, Hyung-Kyu Park, Seo-Young Oh, Hee-Joung Kim, Kye-Young Lee, Wan-Seop Kim
Journal of Korean Medical Science.2016; 31(8): 1224. CrossRef
MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study
Kyueng-Whan Min, Wan-Seop Kim, Se Jin Jang, Yoo Duk Choi, Sunhee Chang, Soon Hee Jung, Lucia Kim, Mee-Sook Roh, Choong Sik Lee, Jung Weon Shim, Mi Jin Kim, Geon Kook Lee
Journal of Cancer Research and Clinical Oncology.2016; 142(10): 2209. CrossRef
Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers
Boram Lee, Taebum Lee, Se-Hoon Lee, Yoon-La Choi, Joungho Han
Oncotarget.2016; 7(17): 23874. CrossRef

Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: Eunhyang Park, Soo Young Park, Hyojin Kim, Ping-Li Sun, Yan Jin, Suk Ki Cho, Kwhanmien Kim, Choon-Taek Lee, Jin-Haeng Chung; J Pathol Transl Med. 2015;49(5):382-388. Published online August 4, 2015; DOI: https://doi.org/10.4132/jptm.2015.07.10

8,117 View
100 Download
22 Web of Science
17 Crossref

Abstract PDF

Background
Insulin-like growth factor-1 receptor (IGF1R) is a membrane receptor-type tyrosine kinase that has attracted considerable attention as a potential therapeutic target, although its clinical significance in non-small cell lung cancer (NSCLC) is controversial. This study aimed to clarify the clinical significance of IGF1R expression in human NSCLC. Methods: IGF1R protein expression was evaluated using immunohistochemistry in 372 patients with NSCLC who underwent curative surgical resection (146 squamous cell carcinomas [SqCCs] and 226 adenocarcinomas [ADCs]). We then analyzed correlations between expression of IGF1R and clinicopathological and molecular features and prognostic significance. Results: Membranous and cytoplasmic IGF1R expression were significantly higher in SqCCs than in ADCs. In patients with SqCC, membranous IGF1R expression was associated with absence of vascular, lymphatic, and perineural invasion; lower stage; and better progression-free survival (PFS) (hazard ratio [HR], 0.586; p = .040). In patients with ADC, IGF1R expression did not have a significant prognostic value; however, in the subgroup of epidermal growth factor receptor (EGFR)-mutant ADC, membranous IGF1R expression was associated with lymphatic and perineural invasion, solid predominant histology, and higher cancer stage and was significantly associated with worse PFS (HR, 2.582; p = .009). Conclusions: Lung ADC and SqCC showed distinct IGF1R expression profiles that demonstrated prognostic significance. High membranous IGF1R expression was predictive of poor PFS in EGFR-mutant lung ADC, while it was predictive of better PFS in SqCC. These findings will help improve study design for subsequent investigations and select patients for future anti-IGF1R therapy.

Citations

Citations to this article as recorded by

Expression of Amine Oxidase Proteins in Adrenal Cortical Neoplasm and Pheochromocytoma
Eun Kyung Kim, Ja Seung Koo
Biomedicines.2023; 11(7): 1896. CrossRef
Expression of EMP 1, 2, and 3 in Adrenal Cortical Neoplasm and Pheochromocytoma
Yoon Jin Cha, Ja Seung Koo
International Journal of Molecular Sciences.2023; 24(16): 13016. CrossRef
Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma
Wenting Liu, Junling Xia, Qingwu Du, Jingya Wang, Ting Mei, Tingting Qin
Journal of Cancer Research and Clinical Oncology.2023; 149(18): 16365. CrossRef
NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells
Lívia Bassani Lins de Miranda, Keli Lima, Juan Luiz Coelho-Silva, Fabiola Traina, Susumu S. Kobayashi, João Agostinho Machado-Neto
Scientific Reports.2022;[Epub] CrossRef
IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
Mi-Sook Lee, Kyungsoo Jung, Ji-Young Song, Min-Jung Sung, Sung-Bin Ahn, Boram Lee, Doo-Yi Oh, Yoon-La Choi
Molecular Therapy - Oncolytics.2020; 16: 188. CrossRef
Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
Tatiana Shaurova, Letian Zhang, David W. Goodrich, Pamela A. Hershberger
Frontiers in Genetics.2020;[Epub] CrossRef
Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity
Hyang Joo Ryu, Eun Kyung Kim, Byoung Chul Cho, Sun Och Yoon
Head & Neck.2019; 41(1): 198. CrossRef
Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection
Yoon Ah Cho, Ji Myung Chung, Hyunmi Ryu, Eun Kyung Kim, Byoung Chul Cho, Sun Och Yoon
Cancer Research and Treatment.2019; 51(3): 1052. CrossRef
NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma
Eun Kyung Kim, Yoon Ah Cho, Mi-kyoung Seo, Hyunmi Ryu, Byoung Chul Cho, Yoon Woo Koh, Sun Och Yoon
Scientific Reports.2019;[Epub] CrossRef
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Qinlian Jiao, Lei Bi, Yidan Ren, Shuliang Song, Qin Wang, Yun-shan Wang
Molecular Cancer.2018;[Epub] CrossRef
The long coding RNA AFAP1-AS1 promotes tumor cell growth and invasion in pancreatic cancer through upregulating the IGF1R oncogene via sequestration of miR-133a
Bo Chen, Qinhua Li, Yongping Zhou, Xujing Wang, Qiqi Zhang, Yongkun Wang, Huiren Zhuang, Xiaohua Jiang, Wujun Xiong
Cell Cycle.2018; 17(16): 1949. CrossRef
Overexpression of lncRNA EGFR‑AS1 is associated with a poor prognosis and promotes chemotherapy resistance in non‑small cell lung cancer
Yu-Hua Xu, Jian-Ren Tu, Tian-Tian Zhao, Shi-Guang Xie, Sheng-Bo Tang
International Journal of Oncology.2018;[Epub] CrossRef
IGF-IR signaling in epithelial to mesenchymal transition and targeting IGF-IR therapy: overview and new insights
Heming Li, Izhar Singh Batth, Xiujuan Qu, Ling Xu, Na Song, Ruoyu Wang, Yunpeng Liu
Molecular Cancer.2017;[Epub] CrossRef
Insulin-like growth factor 1 receptor expression in advanced non-small-cell lung cancer and its impact on overall survival
Mojca Humar, Izidor Kern, Gregor Vlacic, Vedran Hadzic, Tanja Cufer
Radiology and Oncology.2017; 51(2): 195. CrossRef
IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells
Dianna Hussmann, Anne Tranberg Madsen, Kristine Raaby Jakobsen, Yonglun Luo, Boe Sandahl Sorensen, Anders Lade Nielsen
Oncotarget.2017; 8(20): 33300. CrossRef
Upregulated Neuro-oncological Ventral Antigen 1 (NOVA1) Expression Is Specific to Mature and Immature T- and NK-Cell Lymphomas
Eun Kyung Kim, Sun Och Yoon, Soo Hee Kim, Woo Ick Yang, Yoon Ah Cho, Soo Jeong Kim
Journal of Pathology and Translational Medicine.2016; 50(2): 104. CrossRef
The Clinical Significance of the Insulin-Like Growth Factor-1 Receptor Polymorphism in Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
Tu-Chen Liu, Ming-Ju Hsieh, Ming-Che Liu, Whei-Ling Chiang, Thomas Tsao, Shun-Fa Yang
International Journal of Molecular Sciences.2016; 17(5): 763. CrossRef

EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast: Won Hwangbo, Jeong Hyeon Lee, Sangjeong Ahn, Seojin Kim, Kyong Hwa Park, Chul Hwan Kim, Insun Kim; Korean J Pathol. 2013;47(2):107-115. Published online April 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.107

11,668 View
81 Download
14 Crossref

Abstract PDF

Background

The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment.

Methods

A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification.

Results

EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2⁺, EGFR⁺, cytokeratin 5/6^- (CK5/6^-) group, 11.2% of the HER-2^-, EGFR⁺, CK5/6^- group, and 19.1% of the HER-2^-, EGFR⁺, CK5/6⁺ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1⁺ expression cases, 15.9% of 2⁺ expression cases, and 38.5% of 3⁺ expression cases. In group 2, the tumors had a high Ki-67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6.

Conclusions

EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.

Citations

Citations to this article as recorded by

Identification of a cross-talk between EGFR and Wnt/beta-catenin signaling pathways in HepG2 liver cancer cells
Gurjinder Singh, Md Mehedi Hossain, Aadil Qadir Bhat, Mir Owais Ayaz, Nasima Bano, Rafiqa Eachkoti, Mohd Jamal Dar
Cellular Signalling.2021; 79: 109885. CrossRef
Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
Shailendra K. Gautam, Ranjana K. Kanchan, Jawed A. Siddiqui, Shailendra K. Maurya, Sanchita Rauth, Naveenkumar Perumal, Pranita Atri, Ramakanth C. Venkata, Kavita Mallya, Sameer Mirza, Moorthy P. Ponnusamy, Vimla Band, Sidharth Mahapatra, Maneesh Jain, Su
Cancers.2020; 12(10): 2838. CrossRef
Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line
Mona A.M. Abo-Zeid, Mahmoud T. Abo-Elfadl, Amira M. Gamal-Eldeen
Environmental Toxicology and Pharmacology.2019; 71: 103207. CrossRef
Improved characterization of the relationship between long intergenic non‐coding RNA Linc00152 and the occurrence and development of malignancies
Jiasheng Xu, Jingjing Guo, Yangkai Jiang, Yujun Liu, Kaili Liao, Zhonghua Fu, Zhenfang Xiong
Cancer Medicine.2019; 8(10): 4722. CrossRef
Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome
Ge Yan, Mohamed E.M. Saeed, Sebastian Foersch, Jose Schneider, Wilfried Roth, Thomas Efferth
Oncotarget.2019; 10(20): 1918. CrossRef
A novel matrine derivative WM622 inhibits hepatocellular carcinoma by inhibiting PI3K/AKT signaling pathways
Xiao Sun, Xiao-bin Zhuo, Yi-ping Hu, Xuan Zheng, Qing-jie Zhao
Molecular and Cellular Biochemistry.2018; 449(1-2): 47. CrossRef
lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway
Yan Zhang, Cheng Xiang, Yuling Wang, Yuanyuan Duan, Ci Liu, Yongli Jin, Yajing Zhang
Biomedicine & Pharmacotherapy.2017; 94: 644. CrossRef
Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
Areej Fatima, Fomaz Tariq, Muhammad Faraz Arshad Malik, Muhammad Qasim, Farhan Haq
Journal of Breast Cancer.2017; 20(3): 246. CrossRef
Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
Malgorzata Banys-Paluchowski, Isabell Witzel, Sabine Riethdorf, Brigitte Rack, Wolfgang Janni, Peter A. Fasching, Erich-Franz Solomayer, Bahriye Aktas, Sabine Kasimir-Bauer, Klaus Pantel, Tanja Fehm, Volkmar Müller
Scientific Reports.2017;[Epub] CrossRef
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib
James P. De Andrade, Jung M. Park, Vivian W. Gu, George W. Woodfield, Mikhail V. Kulak, Allison W. Lorenzen, Vincent T. Wu, Sarah E. Van Dorin, Philip M. Spanheimer, Ronald J. Weigel
Molecular Cancer Therapeutics.2016; 15(3): 503. CrossRef
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
H J Lee, A N Seo, E J Kim, M H Jang, Y J Kim, J H Kim, S-W Kim, H S Ryu, I A Park, S-A Im, G Gong, K H Jung, H J Kim, S Y Park
British Journal of Cancer.2015; 112(1): 103. CrossRef
Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma
GANG LIN, XIAO-JIANG SUN, QIAN-BO HAN, ZHUN WANG, YA-PING XU, JIA-LEI GU, WEI WU, GU ZHANG, JIN-LIN HU, WEN-YONG SUN, WEI-MIN MAO
Oncology Letters.2015; 10(2): 901. CrossRef
Immunohistochemical Classification of Primary and Secondary Glioblastomas
Kyu Sang Lee, Gheeyoung Choe, Kyung Han Nam, An Na Seo, Sumi Yun, Kyung Ju Kim, Hwa Jin Cho, Sung Hye Park
Korean Journal of Pathology.2013; 47(6): 541. CrossRef
A Comparison of Tumor Biology in Primary Ductal CarcinomaIn SituRecurring as Invasive Carcinoma versus a NewIn Situ
Wenjing Zhou, Christine Johansson, Karin Jirström, Anita Ringberg, Carl Blomqvist, Rose-Marie Amini, Marie-Louise Fjallskog, Fredrik Wärnberg
International Journal of Breast Cancer.2013; 2013: 1. CrossRef

Review & Perspective

Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group: Hyo Sup Shim, Jin-Haeng Chung, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Geon Kook Lee, Soon-Hee Jung, Se Jin Jang; Korean J Pathol. 2013;47(2):100-106. Published online April 24, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.100

9,770 View
85 Download
12 Crossref

Abstract PDF

Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.

Citations

Citations to this article as recorded by

Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer
Insu Kim, Hee Yun Seol, Soo Han Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop Eom
Cancers.2023; 15(5): 1445. CrossRef
Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
Dorine de Jong, Jeeban P. Das, Hong Ma, Jacienta Pailey Valiplackal, Conor Prendergast, Tina Roa, Brian Braumuller, Aileen Deng, Laurent Dercle, Randy Yeh, Mary M. Salvatore, Kathleen M. Capaccione
Cancers.2023; 15(10): 2855. CrossRef
Coordination games in cancer
Péter Bayer, Robert A. Gatenby, Patricia H. McDonald, Derek R. Duckett, Kateřina Staňková, Joel S. Brown, Jun Tanimoto
PLOS ONE.2022; 17(1): e0261578. CrossRef
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group
Sunhee Chang, Hyo Sup Shim, Tae Jung Kim, Yoon-La Choi, Wan Seop Kim, Dong Hoon Shin, Lucia Kim, Heae Surng Park, Geon Kook Lee, Chang Hun Lee
Journal of Pathology and Translational Medicine.2021; 55(3): 181. CrossRef
Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy
Justin J Kuhlman, Muhamad Alhaj Moustafa, Liuyan Jiang, Han W Tun
Journal of Blood Medicine.2021; Volume 12: 833. CrossRef
Molecular Testing of Lung Cancers
Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
Journal of Pathology and Translational Medicine.2017; 51(3): 242. CrossRef
Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience
Choonhee Son, Eun‐Ju Kang, Mee Sook Roh
Diagnostic Cytopathology.2015; 43(7): 532. CrossRef
Ultrasonography-Guided Core Biopsy of Supraclavicular Lymph Nodes for Diagnosis of Metastasis and Identification of Epidermal Growth Factor Receptor (EGFR) Mutation in Advanced Lung Cancer
Jooae Choe, Mi Young Kim, Jung Hwan Baek, Chang-Min Choi, Hwa Jung Kim
Medicine.2015; 94(29): e1209. CrossRef
Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis
Amir Awwad, Sandeep Tiwari, Vishakha Sovani, David R Baldwin, Maruti Kumaran
BMJ Open Respiratory Research.2015; 2(1): e000075. CrossRef
Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non‐small‐cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage
Tae‐Jung Kim, Chan Kwon Park, Chang Dong Yeo, Kihoon Park, Chin Kook Rhee, Jusang Kim, Seung Joon Kim, Sang Haak Lee, Kyo‐Young Lee, Hyoung‐Kyu Yoon
Journal of Surgical Oncology.2014; 110(3): 245. CrossRef
Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry
An Na Seo, Tae-In Park, Yan Jin, Ping-Li Sun, Hyojin Kim, Hyun Chang, Jin-Haeng Chung
Lung Cancer.2014; 83(3): 316. CrossRef
Molecular Pathology of Lung Cancer: Current Status and Future Directions
Mee Sook Roh
Tuberculosis and Respiratory Diseases.2014; 77(2): 49. CrossRef

Original Articles

Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosin: Hyun Ju Lee, Xianhua Xu, Hyojin Kim, Yan Jin, Pingli Sun, Ji Eun Kim, Jin-Haeng Chung; Korean J Pathol. 2013;47(1):52-60. Published online February 25, 2013; DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.1.52

10,611 View
92 Download
31 Crossref

Abstract PDF

Background

The aims of this study were to evaluate the abilities of direct sequencing (DS), peptide nucleic acid (PNA) clamping, and pyrosequencing methods to detect epidermal growth factor receptor (EGFR) mutations in formalin-fixed paraffin-embedded (FFPE) non-small cell lung carcinoma (NSCLC) samples and to correlate EGFR mutational status as determined by each method with the clinical response to EGFR tyrosine kinase inhibitors (TKIs).

Methods

Sixty-one NSCLC patients treated with EGFR TKIs were identified to investigate somatic mutations in the EGFR gene (exons 18-21).

Results

Mutations in the EGFR gene were detected in 38 of the 61 patients (62%) by DS, 35 (57%) by PNA clamping and 37 (61%) by pyrosequencing. A total of 44 mutations (72%) were found by at least one of the three methods, and the concordances among the results were relatively high (82-85%; kappa coefficient, 0.713 to 0.736). There were 15 discordant cases (25%) among the three different methods.

Conclusions

All three EGFR mutation tests had good concordance rates (over 82%) for FFPE samples. These results suggest that if the DNA quality and enrichment of tumor cells are assured, then DS, PNA clamping, and pyrosequencing are appropriate methods for the detection of EGFR mutations.

Citations

Citations to this article as recorded by

Recent Trends of Lung Cancer in Korea
Jae Guk Lee, Ho Cheol Kim, Chang-Min Choi
Tuberculosis and Respiratory Diseases.2021; 84(2): 89. CrossRef
Predictive value of KRAS mutation and excision repair cross-complementing 1 (ERCC1) protein overexpression in patients with colorectal cancer administered FOLFOX regimen
Sun Min Park, Sung Bong Choi, Yoon Suk Lee, In Kyu Lee
Asian Journal of Surgery.2021; 44(5): 715. CrossRef
Recent advances in diagnostic technologies in lung cancer
Hye Jung Park, Sang Hoon Lee, Yoon Soo Chang
The Korean Journal of Internal Medicine.2020; 35(2): 257. CrossRef
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
Sheng-Kai Liang, Jen-Chung Ko, James Chih-Hsin Yang, Jin-Yuan Shih
Lung Cancer.2019; 133: 103. CrossRef
Biomarker Testing for Patients With Advanced Non–Small Cell Lung Cancer: Real-World Issues and Tough Choices
Nathan A. Pennell, Maria E. Arcila, David R. Gandara, Howard West
American Society of Clinical Oncology Educational Book.2019; (39): 531. CrossRef
Evaluation of EGFR mutations in NSCLC with highly sensitive droplet digital PCR assays
Xi‑Wen Jiang, Wei Liu, Xiao‑Ya Zhu, Xiao‑Xie Xu
Molecular Medicine Reports.2019;[Epub] CrossRef
Peptide Nucleic Acid Clamping and Direct Sequencing in the Detection of Oncogenic Alterations in Lung Cancer: Systematic Review and Meta-Analysis
Jae-Uk Song, Jonghoo Lee
Yonsei Medical Journal.2018; 59(2): 211. CrossRef
Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
Zahra Fathi, Seyed Ali Javad Mousavi, Raheleh Roudi, Farideh Ghazi, Sumitra Deb
PLOS ONE.2018; 13(7): e0200633. CrossRef
EGFR T790M mutation testing within the osimertinib AURA Phase I study
Simon Dearden, Helen Brown, Suzanne Jenkins, Kenneth S. Thress, Mireille Cantarini, Rebecca Cole, Malcolm Ranson, Pasi A. Jänne
Lung Cancer.2017; 109: 9. CrossRef
Molecular Testing of Lung Cancers
Hyo Sup Shim, Yoon-La Choi, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Mee Sook Roh, Tae-Jung Kim, Seung Yeon Ha, Jin-Haeng Chung, Se Jin Jang, Geon Kook Lee
Journal of Pathology and Translational Medicine.2017; 51(3): 242. CrossRef
Mutations of the Epidermal Growth Factor Receptor Gene in Triple-Negative Breast Cancer
Aeri Kim, Min Hye Jang, Soo Jung Lee, Young Kyung Bae
Journal of Breast Cancer.2017; 20(2): 150. CrossRef
Double primary lung adenocarcinoma diagnosed by epidermal growth factor receptor mutation status
Oh Jung Kwon, Min Hyeok Lee, Sung Ju Kang, Seul Gi Kim, In Beom Jeong, Ji Yun Jeong, Eun Jung Cha, Do Yeun Cho, Young Jin Kim, Ji Woong Son
Yeungnam University Journal of Medicine.2017; 34(2): 270. CrossRef
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
Mi-Young Park, Min Hee Jung, Eun Young Eo, Seokjoong Kim, Sang Hoon Lee, Yeon Joo Lee, Jong Sun Park, Young Jae Cho, Jin Haeng Chung, Cheol Hyeon Kim, Ho Il Yoon, Jae Ho Lee, Choon-Taek Lee
Oncotarget.2017; 8(22): 36331. CrossRef
Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study
Kyueng-Whan Min, Wan-Seop Kim, Se Jin Jang, Yoo Duk Choi, Sunhee Chang, Soon Hee Jung, Lucia Kim, Mee Sook Roh, Choong Sik Lee, Jung Weon Shim, Mi Jin Kim, Geon Kook Lee
QJM.2016; 109(3): 167. CrossRef
Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis
Yi-Lin Chen, Chung-Ta Lee, Cheng-Chan Lu, Shu-Ching Yang, Wan-Li Chen, Yang-Cheng Lee, Chung-Hsien Yang, Shu-Ling Peng, Wu-Chou Su, Nan-Haw Chow, Chung-Liang Ho, Javier S Castresana
PLOS ONE.2016; 11(6): e0158125. CrossRef
IDH Mutation Analysis in Ewing Sarcoma Family Tumors
Ki Yong Na, Byeong-Joo Noh, Ji-Youn Sung, Youn Wha Kim, Eduardo Santini Araujo, Yong-Koo Park
Journal of Pathology and Translational Medicine.2015; 49(3): 257. CrossRef
Immunohistochemical demonstration of alteration of β-catenin during tumor metastasis by different mechanisms according to histology in lung cancer
XIANHUA XU, JI EUN KIM, PING-LI SUN, SEOL BONG YOO, HYOJIN KIM, YAN JIN, JIN-HAENG CHUNG
Experimental and Therapeutic Medicine.2015; 9(2): 311. CrossRef
Detection of EGFR-TK Domain–activating Mutations in NSCLC With Generic PCR-based Methods
Rajendra B. Shahi, Sylvia De Brakeleer, Jacques De Grève, Caroline Geers, Peter In’t Veld, Erik Teugels
Applied Immunohistochemistry & Molecular Morphology.2015; 23(3): 163. CrossRef
Frequent aerogenous spread with decreased E-cadherin expression of ROS1- rearranged lung cancer predicts poor disease-free survival
Yan Jin, Ping-Li Sun, Soo Young Park, Hyojin Kim, Eunhyang Park, Gilhyang Kim, Sukki Cho, Kwhanmien Kim, Choon-Taek Lee, Jin-Haeng Chung
Lung Cancer.2015; 89(3): 343. CrossRef
Membranous Insulin-like Growth Factor-1 Receptor (IGF1R) Expression Is Predictive of Poor Prognosis in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma
Eunhyang Park, Soo Young Park, Hyojin Kim, Ping-Li Sun, Yan Jin, Suk Ki Cho, Kwhanmien Kim, Choon-Taek Lee, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2015; 49(5): 382. CrossRef
Peptide Nucleic Acid Clamping Versus Direct Sequencing for the Detection of EGFR Gene Mutation in Patients with Non-small Cell Lung Cancer
Seong-Hoon Yoon, Yoo-Duk Choi, In-Jae Oh, Kyu-Sik Kim, Hayoung Choi, Jinsun Chang, Hong-Joon Shin, Cheol-Kyu Park, Young-Chul Kim
Cancer Research and Treatment.2015; 47(4): 661. CrossRef
Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey
Sang Hwa Lee, Wan Seop Kim, Yoo Duk Choi, Jeong Wook Seo, Joung Ho Han, Mi Jin Kim, Lucia Kim, Geon Kook Lee, Chang Hun Lee, Mee Hye Oh, Gou Young Kim, Sun Hee Sung, Kyo Young Lee, Sun Hee Chang, Mee Sook Rho, Han Kyeom Kim, Soon Hee Jung, Se Jin Jang
Journal of Pathology and Translational Medicine.2015; 49(6): 481. CrossRef
Novel EGFR mutation-specific antibodies for lung adenocarcinoma: Highly specific but not sensitive detection of an E746_A750 deletion in exon 19 and an L858R mutation in exon 21 by immunohistochemistry
An Na Seo, Tae-In Park, Yan Jin, Ping-Li Sun, Hyojin Kim, Hyun Chang, Jin-Haeng Chung
Lung Cancer.2014; 83(3): 316. CrossRef
Simultaneous diagnostic platform of genotyping EGFR, KRAS, and ALK in 510 Korean patients with non‐small‐cell lung cancer highlights significantly higher ALK rearrangement rate in advanced stage
Tae‐Jung Kim, Chan Kwon Park, Chang Dong Yeo, Kihoon Park, Chin Kook Rhee, Jusang Kim, Seung Joon Kim, Sang Haak Lee, Kyo‐Young Lee, Hyoung‐Kyu Yoon
Journal of Surgical Oncology.2014; 110(3): 245. CrossRef
Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity
Sung-Jun Ko, Yeon Joo Lee, Jong Sun Park, Young-Jae Cho, Ho Il Yoon, Jin-Haeng Chung, Tae Jung Kim, Kyung Won Lee, Kwhanmien Kim, Sanghoon Jheon, Hyojin Kim, Jae Ho Lee, Choon-Taek Lee
BMC Cancer.2014;[Epub] CrossRef
Cytoplasmic YAP Expression is Associated with Prolonged Survival in Patients with Lung Adenocarcinomas and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment
Ping-Li Sun, Ji Eun Kim, Seol Bong Yoo, Hyojin Kim, Yan Jin, Sanghoon Jheon, Kwhanmien Kim, Choon Taek Lee, Jin-Haeng Chung
Annals of Surgical Oncology.2014; 21(S4): 610. CrossRef
Sensitive methods for detection of the S768R substitution in exon 18 of the DDR2 gene in patients with central nervous system metastases of non-small cell lung cancer
Marcin Nicoś, Tomasz Powrózek, Paweł Krawczyk, Bożena Jarosz, Beata Pająk, Marek Sawicki, Krzysztof Kucharczyk, Tomasz Trojanowski, Janusz Milanowski
Medical Oncology.2014;[Epub] CrossRef
Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas
A N Seo, J M Yang, H Kim, S Jheon, K Kim, C T Lee, Y Jin, S Yun, J-H Chung, J H Paik
British Journal of Cancer.2014; 110(11): 2688. CrossRef
KRASMutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing
Boram Lee, Boin Lee, Gangmin Han, Mi Jung Kwon, Joungho Han, Yoon-La Choi
Korean Journal of Pathology.2014; 48(2): 100. CrossRef
Guideline Recommendations forEGFRMutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group
Hyo Sup Shim, Jin-Haeng Chung, Lucia Kim, Sunhee Chang, Wan-Seop Kim, Geon Kook Lee, Soon-Hee Jung, Se Jin Jang
Korean Journal of Pathology.2013; 47(2): 100. CrossRef
Immunohistochemical Classification of Primary and Secondary Glioblastomas
Kyu Sang Lee, Gheeyoung Choe, Kyung Han Nam, An Na Seo, Sumi Yun, Kyung Ju Kim, Hwa Jin Cho, Sung Hye Park
Korean Journal of Pathology.2013; 47(6): 541. CrossRef

Intron 1 Polymorphism, Mutation and the Protein Expression of Epidermal Growth Factor Receptor in Relation to the Gefitinib Sensitivity of Korean Lung Cancer Patients.: Mi Jin Kim, Kyeong Cheol Shin, Kwan Ho Lee; Korean J Pathol. 2009;43(6):509-516.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.6.509

2,869 View
16 Download

Abstract PDF: BACKGROUND
Epidermal growth factor receptor (EGFR) intron 1 polymorphism in non-small cell lung cancer (NSCLC) has been found to have therapeutic implications for the patients treated with EGFR tyrosine kinase inhibitors. However, its clinical significance as related to gefitinib responsiveness is still controversial. We examined CA repeat polymorphism in intron 1 of the EGFR gene and its relation with the EGFR gene mutation in NSCLC patients who were treated with gefitinib. METHODS: Sixty seven patients who were treated with gefitinib were analyzed for intron 1 polymorphism in the EGFR gene, the EGFR mutations and the EGFR protein expression. Two hundred twenty seven samples of NSCLC were analyzed for EGFR mutations. RESULTS: CA repeat was low in 27 patients (40.3%) and high in 40 (59.7%) patients. The response rate for gefitinib therapy was higher in the patient population with a low number of CA repeats in the EGFR gene (p=0.047) and in the patients with the mutated type of EGFR (p=0.048), though these two factors were not related. Thirty four patients (15.0%) harbored EGFR mutations. CONCLUSIONS: This study suggests that the intron 1 CA repeat polymorphism of the EGFR gene may serve as a predictor of the clinical outcome of NSCLC patients treated with gefitinib, and this without regard for EGFR mutation. Our data further supports the importance of EGFR mutations with regard to a distinct clinical profile and the prognostic implications for NSCLC patients.

Epidermal Growth Factor Receptor Expression of Non-small Cell Carcinoma and Its Relationship with Genomic Mutation.: Sang hee Seok, Mi Jin Kim; Korean J Pathol. 2008;42(2):94-99.

1,755 View
26 Download

Abstract PDF: BACKGROUND
It has recently been clarified that epidermal growth factor receptor (EGFR), which is a receptor tyrosine kinase of the erbB family, is abnormally activated in non-small cell lung carcinomas (NSCLC) and this fact is being utilized for creating targeted therapy. In this study, we aimed to identify the frequency of the EGFR expression and gene mutation in NSCLC, and to determine the correlation between them.
METHODS
Immunohistochemical staining for EGFR, C-erbB-2, cytokeratin 7, p53 and thyroid transcription factor-1, and EGFR mutation analysis were performed using paraffin-embedded archival tissue from 228 cases of NSCLC; this included 112 squamous cell carcinomas and 116 adenocarcinomas.
RESULTS
An EGFR expression and gene mutation occurred in 112 casees (53.5%) and 52 cases (22.8%), respectively. EGRF mutation was more frequent in the adenocarcinomas than in the squamous cell carcinomas, in non-smokers than in smokers, and in females than in males. EGFR mutation was significantly associated with an EGFR protein expression, and especially in adenocarcinomas.
CONCLUSION
The EGFR expression in NSCLC was associated with EGFR mutation, and especially in adenocarcinomas. More studies are needed to prove the clinical significance of the EGFR expression for creating targeted therapy to treat NSCLC.

First
Prev
Page of 1
Next
Last

Search